Retatrutide vs Survodutide
Both Retatrutide and Survodutide are used for weight-loss and metabolic. Here's how their evidence, dosing, and regulatory status actually compare.
Retatrutide
Evidence ARetatrutide (LY3437943)
Triple agonist at GLP-1, GIP, and glucagon receptors. Phase 2 produced 24.2% mean weight reduction at 48 weeks — the highest ever in a clinical obesity trial.
View full Retatrutide profile →Survodutide
Evidence ASurvodutide (BI 456906)
A dual GLP-1 / glucagon receptor agonist with strong Phase 2 weight-loss and MASH data. Resolution of MASH in 83% of participants at the highest dose at week 48.
View full Survodutide profile →Side-by-Side
| Attribute | Retatrutide | Survodutide |
|---|---|---|
| Evidence Grade | A | A |
| FDA Status | Not FDA-approved — Phase 3 trials (TRIUMPH program) for obesity | Not FDA-approved — Phase 3 trials for obesity and MASH |
| Typical Dose | Trial range: 1–12 mg weekly (subcutaneous) | Trial range: 0.6–6 mg weekly (subcutaneous) |
| Clinics Indexed | 12 | 6 |
| Categories | weight-loss, metabolic | weight-loss, metabolic |
Key reported benefits — Retatrutide
- ✓Highest reported weight loss
- ✓Triple incretin/glucagon mechanism
- ✓Metabolic improvement
Key reported benefits — Survodutide
- ✓Weight loss
- ✓MASH resolution
- ✓Glucose control
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.